SIGLEC1 enables straightforward assessment of type I interferon ...

SIGLEC1 is a candidate biomarker to assess type I interferon activity in IIM and proved useful for monitoring disease activity and response to treatment in ...

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.

SIGLEC1 enables straightforward assessment of type I interferon ...

SIGLEC1 expression is a suitable biomarker for monitoring type I interferon activation in rheumatic musculoskeletal diseases, which has clinical ...

SIGLEC1 enables straightforward assessment of type I interferon ...

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. Loading. You need to be signed in to access ...

(PDF) SIGLEC1 enables straightforward assessment of type I ...

PDF | Objective To evaluate sialic acid binding Ig-like lectin 1 (SIGLEC1) expression on monocytes by flow cytometry as a type I interferon ...

SIGLEC1 enables straightforward assessment of type I interferon ...

Request PDF | SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies | Objective: To ...

SIGLEC1 enables straightforward assessment of type I interferon ...

ObjectiveTo evaluate sialic acid binding Ig-like lectin 1 (SIGLEC1) expression on monocytes by flow cytometry as a type I interferon ...

SIGLEC1 enables straightforward assessment of type I interferon...

2 reagents referenced in SIGLEC1 enables straightforward assessment of type I interferon activity in inflammatory myopathies.

SIGLEC1 enables straightforward assessment of type I interferon ...

Abstract ObjectiveTo evaluate SIGLEC1 expression on monocytes by flow cytometry as a type I interferon biomarker in idiopathic inflammatory myopathies (IIM) ...

Siglec-1 expression on monocytes is associated with the interferon ...

27 Citations · SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies · Role of CD14+ monocyte-derived ...

CD169 expression on monocytes as a marker for assessing type I ...

... type 1 IFN-mediated diseases. Keywords: CD169 ... Rose,. SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory.

SIGLEC1 enables straightforward assessment of type I interferon ...

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. Manuel Graf, Sae Lim von Stuckrad, Akinori ...

SIGLEC1 enables straightforward assessment of type ... - Labor Berlin

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. Labor Berlin · News · SIGLEC1 enables ...

SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential ...

For myositis, SIGLEC-1 was found to be a candidate biomarker to assess type I IFN activity. ... SIGLEC1 enables straightforward assessment of type ...

Siglec-1 expression on monocytes is associated with the interferon ...

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. Manuel Graf, Sae Lim von Stuckrad, Akinori ...

SIGLEC1 (sialic acid binding Ig like lectin 1)

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. 6. 35695299, 2022, The role of ...

Rheumatology | medRxiv

SIGLEC1 enables straightforward assessment of type I interferon activity in inflammatory myopathies. Manuel Graf, Sae Lim von Stuckrad, Akinori Uruha, Jens ...

SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of ...

Type I interferon in systemic lupus erythematosus and other ... SIGLEC1 enables straightforward assessment of type I interferon activi...

SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of ...

... type I IFN signature with sialic acid-binding immunoglobulin ... SIGLEC1 enables straightforward assessment of type I interferon activi...

Update on Novel Blood-Based Biomarkers for Lupus Nephritis ...

SIGLEC1 enables straightforward assessment of Type I interferon activity in idiopathic inflammatory myopathies. RMD Open. 2022;8:e001934. [ Links ]. 12 ...